Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning.
AffiliationRoyal Postgraduate Medical School, London.
MetadataShow full item record
AbstractBetween July 1986 and March 1991, 16 patients who had relapsed after T-lymphocyte depleted bone marrow transplantation (BMT) for chronic myeloid leukaemia (CML) received a second transplant using unmanipulated marrow cells from the same HLA-identical sibling donor. The median numbers of days from first BMT to haematological relapse and to second BMT were 557 (range 273-1543) and 1211 (range 476-2310) respectively. 11 patients were in uncomplicated chronic phase at time of second BMT, and five had more advanced disease. As conditioning for second BMT, eight patients received various combinations of cytotoxic drugs, and eight received high-dose busulphan alone. Eight (50%) patients survive at a median of 424 d post-second BMT (range 158-1789) and all are free of leukaemia by conventional criteria: five had been conditioned with high-dose busulphan alone. Causes of death in the eight patients who died included relapse (n = 2), graft-versus-host disease (n = 2), interstitial pneumonitis (n = 2), and infection (n = 2). We conclude that patients relapsing into chronic phase after BMT with T-lymphocyte depleted donor marrow may be offered the option of second BMT with unmanipulated marrow from the original donor. Conditioning with high-dose busulphan alone may be safer than use of more intensive schedules.
CitationSecond transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning. 1992, 80 (1):33-9 Br J Haematol
JournalBritish Journal of Haematology
- Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
- Authors: Pichert G, Roy DC, Gonin R, Alyea EP, Bélanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C
- Issue date: 1995 Jul
- Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow.
- Authors: Hughes TP, Economou K, Mackinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM
- Issue date: 1989 Dec
- HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome.
- Authors: Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarer AP, Mackinnon S, Apperley J, Barrett AJ, Hows JM
- Issue date: 1992 Jul
- Five year leukaemia-free survival of 72% and 77% for early stage acute and chronic myeloid leukaemia treated by HLA-identical sibling bone marrow transplantation.
- Authors: Atkinson K, Downs K, Dodds A, Concannon A, Milliken S
- Issue date: 1996 Feb
- Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
- Authors: Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S
- Issue date: 2004 Mar-Apr